News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘Immunotherapy’ clear

  • Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.

Tags: Melanoma, Immunotherapy

  • Researchers reported survival of patients with advanced melanoma was improved when they received an immune stimulant along with a checkpoint blocker immunotherapy drug. The combination also resulted in fewer serious side effects compared with patients who got only the immunotherapy drug, ipilimumab.

Tags: Melanoma, Immunotherapy

  • Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.

Tags: BasicResearch, LungCancer, Immunotherapy

  • F. Stephen Hodi, MD, and colleagues report the immunotherapy drug nivolumab continues to show long-term effectiveness in treating metastatic melanoma, achieving a three-year survival rate of 41 percent against the deadly skin cancer.

Tags: Melanoma, Immunotherapy

  • Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.

Tags: LungCancer, Immunotherapy

  • Nivolumab, a drug that unleashes the immune system to attack cancer, now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by Dana-Farber researchers and colleagues.

Tags: Melanoma, Immunotherapy

  • Dana-Farber researchers found that in patients with advanced melanoma using the immunotherapy ipilimumab, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in the blood was associated with a poorer response, suggesting that combining immunotherapy with VEGF inhibitors may be a potential option for these patients.

Tags: Melanoma, SkinCancer, Immunotherapy

  • The FDA's approval of Provenge®, a prostate cancer vaccine, marks a new era of using patients' immune systems to treat cancer.

Tags: ImmuneSystem, ProstateCancer, TranslationalResearch, Immunotherapy

Showing 1-8 of 8 items